Administer once every four weeks by subcutaneous injection¹

For patients aged 18 years and older:

CRYSVITA is administered by subcutaneous injection and should be administered by a health professional.

RECOMMENDED INITIAL DOSE:
1 mg/kg of body weight
Round to the nearest 10 mg up to a maximum dose of 90 mg.

MAXIMUM DOSE:
90 mg
CRYSVITA should not be administered at doses greater than 1 mg/kg in adults with XLH.

Recalculate dose if there are changes in patient weight of ±10%.

Monitoring for dose adjustments:

Measure fasting serum phosphorus on a monthly basis, measured 2 weeks post-dose, for the first 3 months of treatment, and thereafter as appropriate.

Dose calculator for adults with XLH

Use the dosing calculator to determine your adult patients’ dose and the vials needed.

Dose:

X mg every 4 weeks

Vials needed
(mg/mL):

Remember to recalculate dose if there are changes in patient weight of ±10%.

See CRYSVITA Product Monograph for complete dosing and administration instructions.

Dose adjustments for adult patients with XLH¹

If serum phosphorus is within the normal range:

Continue treatment with the same dose.

If serum phosphorus is above the normal range:

Withhold the next dose and reassess the serum phosphorus level in 4 weeks. The patient must have serum phosphorus below the normal range to be able to reinitiate CRYSVITA.

Once serum phosphorus is below the normal range, restart CRYSVITA at half the previous recommended initial dose up to a maximum dose of 40 mg every 4 weeks.

Reassess serum phosphorus 2 weeks after any change in dose. Do not adjust CRYSVITA dose more frequently than every 4 weeks.

See CRYSVITA Product Monograph for complete dosing and administration instructions.

Administration of CRYSVITA

CRYSVITA is administered by subcutaneous injection and should be administered by a health professional based on the patient’s age and body weight.¹

If a given dose requires multiple vials of CRYSVITA, contents from two vials can be combined for injection (the maximum volume per injection is 1.5 mL).¹

If multiple injections are required, administer at different injection sites.

CRYSVITA comes in 3 strengths¹

Not actual size.

Injection sites should be rotated, with each injection administered at a different anatomic location than the previous injection. Injection sites include:¹

Upper arms
Upper thighs
Buttocks
Any quadrant of the abdomen

Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.

See CRYSVITA Product Monograph for complete dosing and administration instructions.

Reference: CRYSVITA (burosumab injection) Product Monograph. Kyowa Kirin Inc. March 15, 2023.

Administer once every four weeks by subcutaneous injection1

For patients aged 18 years and older:

Administer once every four weeks by subcutaneous injection¹